Will Radiomics Replace Sentinel Lymph Node Biopsy?

Abstract

Axillary lymph node metastasis is by far the most vital determinant of survival for breast cancer patients (1). Sentinel lymph node biopsy (SLNB) is the gold standard for axillary lymph node staging in clinically node-negative patients. However, despite the reported high sensitivity (44%–100%) and specificity (100%) of SLNB (2), it is associated with multiple morbidities, including sensory impairment, motor dysfunction, and lymphedema (3). to predict axillary lymph node status in breast cancer patients. Magnetic resonance imaging, computed tomography, and mammography are usually used as the image sources to build the predictive model. The results of radiomics are promising, with an accuracy, sensitivity, and specificity as high as 98% (5). Although radiomics shows high accuracy in predicting axillary lymph node metastasis, it is not expected to replace SLNB in the near future. This is because the evidence from current radiomics studies is of modest quality. To date, almost all radiomics studies are retrospective in design and lack comparison with the gold standard. Moreover, most of the studies lack external validation and cost-effectiveness analysis. We believe that replacing SLNB with radiomics in axillary lymph node staging in breast cancer is possible and will spare millions of patients unnecessary surgical interventions. However, implementing radiomics in breast cancer care requires robust evidence from randomized controlled trials. Whether or not the current evidence from the retrospective studies justifies clinical trials is yet to be determined. The answer to this question may be solved by conducting a meta-analysis of the existing literature.